<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03595254</url>
  </required_header>
  <id_info>
    <org_study_id>MSchure</org_study_id>
    <nct_id>NCT03595254</nct_id>
  </id_info>
  <brief_title>Digital Cognitive Behavior Therapy Program for Suicide Prevention</brief_title>
  <acronym>TM2</acronym>
  <official_title>Thrive-Montana: A Computerized Cognitive Behavior Therapy (cCBT) Program to Reduce Depression, Anxiety, Suicidal Ideation and Behaviors for Rural Montanans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montana State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Montana Department of Public Health and Human Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montana State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy&#xD;
      program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among&#xD;
      adults. The first 450 participants will participate in a randomized waitlist controlled&#xD;
      trial. The remaining 550 participants will be provided the program immediately upon enrolling&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of Thrive has been studied among patient and community populations and has shown&#xD;
      to effectively reduce depression and anxiety symptoms among adults with moderate to severe&#xD;
      depression symptoms at baseline.&#xD;
&#xD;
      This study will examine whether Thrive can also reduce suicidal thinking for persons&#xD;
      exhibiting at least moderate depression symptoms. The first phase of the study will implement&#xD;
      a randomized waitlist controlled trial. The second phase of the study will examine the&#xD;
      effects in a open trial. Outcome assessments will occur at baseline, 4- and 8-weeks (12- and&#xD;
      16-weeks for the waitlist group) with a 6-month follow-up assessment for all participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Actual">April 8, 2020</completion_date>
  <primary_completion_date type="Actual">April 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized waitlist controlled trial (first ?? participants) Open trial (following ?? participants)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concise Health Risk Tracking</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Suicidal Thinking; Score range 7 (better) - 35(worse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Generalized Anxiety Disorder Scale-7</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Anxiety symptoms; Score range 0 (better) to 21 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work and Social Adjustment Scale</measure>
    <time_frame>1 Year</time_frame>
    <description>Functioning; Score range 0(better) - 40(worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connor-Davidson Resilience Scale - Abbreviated Version</measure>
    <time_frame>1 month</time_frame>
    <description>Resilience; score range 0 (worse) - 40(better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-9</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Depression; Score range 0(better) - 27(worse)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">725</enrollment>
  <condition>Suicidal Ideation</condition>
  <condition>Depression</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Thrive Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Online cognitive behavior therapy program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Wait 8 weeks before receiving program access</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Thrive</intervention_name>
    <description>Computerized Cognitive Behavior Therapy program</description>
    <arm_group_label>Thrive Intervention</arm_group_label>
    <other_name>Thrive-Montana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Montana resident&#xD;
&#xD;
          -  18+ years old&#xD;
&#xD;
          -  Have regular access to broadband internet&#xD;
&#xD;
          -  PHQ-9 score greater than 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No Montana residency&#xD;
&#xD;
          -  &lt; 18 years old&#xD;
&#xD;
          -  No broadband internet access&#xD;
&#xD;
          -  PHQ-9 score less than 5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montana State University</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59717-2940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2018</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montana State University</investigator_affiliation>
    <investigator_full_name>Mark B. Schure, Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

